Browse > Article

New Prognostic Significance of Malignant Pleural Effusion In Patients with Non-Small Cell Lung Cancer  

Kim, So-Young (Department of Internal Medicine, Wonkwang University)
Park, Seong-Hoon (Department of Radiology, Wonkwang University)
Shin, Jeong-Hyun (Department of Internal Medicine, Wonkwang University)
Shin, Seong-Nam (Department of Internal Medicine, Wonkwang University)
Kim, Dong (Department of Internal Medicine, Wonkwang University)
Lee, Mi-Kung (Department of Thoracic Surgery, Wonkwang University)
Lee, Sam-Youn (Department of Thoracic Surgery, Wonkwang University)
Choi, Soon-Ho (Department of Thoracic Surgery, Wonkwang University)
Kim, Hak-Ryul (Department of Internal Medicine, Wonkwang University)
Jeong, Eun-Taik (Department of Internal Medicine, Wonkwang University)
Moon, Sun-Rock (Department of Radiation Oncology, Wonkwang University)
Lee, Kang-Kyu (Department of Radiation Oncology, Wonkwang University)
Yang, Sei-Hoon (Department of Internal Medicine, Wonkwang University)
Publication Information
Journal of Physiology & Pathology in Korean Medicine / v.23, no.3, 2009 , pp. 710-714 More about this Journal
Abstract
Several studies showed that the survival rate of stage IIIB disease with malignant pleural effusion is worse than stage IIIB disease without malignant effusion. But, malignant pleural effusion was considered T4. To analyze changes the survival time for malignant pleural effusion, in the seventh revision of TNM classification for lung cancer. The records of all patients had to have either a histological or cytological diagnosis of non-small cell lung cancer (NSCLC), who were admitted to Wonkwang university hospital between January 2004 and December 2006 were reviewed retrospectively. We evaluated the survival time of 187 patients with advanced lung cancer with and without malignant pleural effusion. This included the pleural effusion or nodule M1 a (pleural dissemination, currently classified as T4), nodule(s) in the other lung M1 a (contralateral lung nodule, currently classified as M1), nodule(s) with the same lobe as the primary tumor T3 (currently classified as T4), other T4 factors T4 (T4 MO anyN), and extrathoracic sites of disease M1b (distant metastasis, currently classified M1). Among the 187 patients, T4anyNMO was 57 patients in the current TNM classification. In the next edition of the TNM classification, T4MOanyN-T4 (excluding same lobe nodules) was 12 patients, pleural dissemiantion-M1a was 45 patients, contralateral lung nodule(s)-M1a was 7 patients, and metastatic disease-M1b was 55 patients. We compared the survival time for these groups. Survival time was 11 months, 8 months, 11 months, and 4 months. The survival time of malignant pleural effusion was shorter than other T4 factors without pleural effusion. But, there was no remarkable difference in statistics due to small cases (p=0.23). We strongly suggest that malignant pleural effusion in advanced NSCLC will be categorized with metastatic disease.
Keywords
malignant pleural effusion; TNM staging; NSCLC; Survival;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Leong, S.S., Rocha Lima, C.M., Sherman, C.A.. The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed?. Chest. 115: 242-248, 1999   DOI   ScienceOn
2 van de Molengraft, F.J., Vooijs, G.P. Survival of patients with malignancy-associated effusions. Acta Cytol. 33: 911-916, 1989   PUBMED
3 Monte, S.A., Ehya, H., Lang, W.R. Positive effusion cytology as the initial presentation of malignancy. Acta Cytol. 31: 448-452, 1987   PUBMED
4 Naruke, T., Tsuchiya, R., Kondo, H. Implications of staging in lung cancer. Chest. 112: 242S-248S, 1997   DOI   ScienceOn
5 Sears, D., Hajdu, S.I. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol. 31: 85-97, 1987   PUBMED
6 Mountain, C.F. A new international staging system for lung cancer. Chest. 89: 225S-233S, 1986   DOI   PUBMED
7 Rusch, V.W., Crowley, J., Giroux, D.J. The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2: 603-612, 2007   DOI   ScienceOn
8 Sobin, L., Wittekind, C.h. (Eds.) TNM Classification of Malignant Tumours, 6th Ed. New York, Wiley-Liss, pp 99-103, 2002
9 Jett, J.R., Scott, W.J., Rivera, M.P. Guidelines on treatment of stage IIIB non-small cell lung cancer. Chest. 123: 221S-225S, 2003   DOI   PUBMED   ScienceOn
10 Rami-Porta, R., Ball, D., Crowley, J. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2: 593-602, 2007   DOI   ScienceOn
11 Socinski, M.A., Morris, D.E., Masters, G.A. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 123: 226S-243S, 2003   DOI   PUBMED   ScienceOn
12 Mountain, C.F. Revision in the international staging system for lung cancer. Chest 111: 1710-1717, 1997   DOI   PUBMED   ScienceOn
13 Goldstraw, P., Crowley, J., Chansky, K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2: 706-714, 2007   DOI   ScienceOn
14 Ou, S.H., Zell, J.A. Validation study of the proposed IASLC staging revisions of the T4 and M non-small cell lung cancer descriptors using data from 23,583 patients in the California Cancer Registry. J Thorac Oncol. 3: 216-227, 2008   DOI   ScienceOn
15 Alon, B.N., Anson, B.L. Pleural effusion in patients with non-small cell carcinoma--stage IV and not T4. Lung Cancer. 57: 123, 2007   DOI   ScienceOn
16 Postmus, P.E., Brambilla, E., Chansky, K. The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol. 2: 686-693, 2007   DOI   ScienceOn
17 Pujol, J.L., Chakra, M. Staging metastasis profile of non-small cell lung cancer: a new paradigm? J Thorac Oncol. 2: 679-681, 2007   DOI   ScienceOn
18 Sugiura, S., Ando, Y., Hironobu, M. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res. 3: 47-50, 1997